Where is Dendreon located?
Dendreon corporate headquarters and immunotherapy manufacturing facility, Seal Beach, California.
Who is the CEO of Dendreon?
Jim Caggiano (Jun 2017–)Dendreon / CEO
Why did Dendreon fail?
We conclude that the bankruptcy of Dendreon was largely due to the delay in securing FDA approval and CMS coverage, as well as the high cost that had to be incurred by providers up-front.
Is Dendreon public?
Once a public company based in Seattle, Dendreon is now a private company based in Seal Beach, Calif.
Who bought Dendreon?
Sanpower Group
On January 9, 2017 Sanpower Group agrees to acquire Dendreon from Valeant for $819.9 million In June 2017, Sanpower Group, a Chinese conglomerate, purchased Dendreon from Valeant for $820 million.
What is the cost of Dendreon?
Each infusion of Provenge will cost $31,000, bringing the full cost of treatment for three infusions to $93,000. As the company put it, the drug will cost about $23,000 per month of life extension, based on the Phase III study that found the drug extended life by 4.1 months.
Who acquired Dendreon?
Sanpower
Nanjing Cenbest—one of China’s largest retailers, which recently branched out into healthcare—bought Dendreon by issuing Sanpower, already its largest shareholder, 180 million additional shares of its Shanghai-listed stock at 33.02 Chinese yuan ($4.80) apiece.
What happened Dendreon stock?
Dendreon’s stock value fell 66% on August 4, 2011, after abandoning its forecast for its debut drug Provenge. On January 9, 2017 Sanpower Group agrees to acquire Dendreon from Valeant for $819.9 million In June 2017, Sanpower Group, a Chinese conglomerate, purchased Dendreon from Valeant for $820 million.
What is the cost of a Keytruda infusion?
The list price for each indicated dose of KEYTRUDA when given every 3 weeks is $10,268.72. The list price for each indicated dose of KEYTRUDA when given every 6 weeks is $20,537.44. *† Most people will not pay the list price, although it may have an impact on your out-of-pocket costs.
Is there a vaccine for prostate?
To date, the only prostate cancer vaccine that has completed Phase III trials and has been approved and licensed by the US FDA is Sipuleucel-T, which immunizes patients against the prostate-associated antigen prostatic acid phosphatase.
What cancers is Keytruda approved for?
Keytruda is used alone or with other drugs to treat certain types of breast cancer, skin cancer (squamous cell carcinoma of the skin, Merkel cell carcinoma, and melanoma), colorectal cancer, endometrial cancer, renal cell carcinoma (a type of kidney cancer), esophageal cancer, gastroesophageal junction cancer, stomach …
Why is Keytruda so expensive?
If Keytruda® is not subsidised, the estimated cost is A$150,000 per patient for each year of treatment. Why so expensive? The pharmaceutical industry points to the costs of research and development, including the expense of the large clinical trials needed to confirm efficacy.